AI-generated research brief — verify at source
CBT Shows Strongest and Most Consistent Benefits Across Resilience, Anxiety, and Depression in Cancer Patients
In a network meta-analysis of 26 randomized controlled trials, cognitive behavioral therapy (CBT) produced the largest improvement in resilience among adults with cancer, with an effect size roughly one standard deviation above control conditions (SMD = 1.14, 95% CI: 0.80–1.48), and also demonstrated significant reductions in both anxiety and depression. While Acceptance and Commitment Therapy (ACT) showed a numerically larger average anxiety reduction, CBT was the only intervention to achieve consistent, statistically significant benefits across all three psychological outcomes examined.
What Was Studied
This study investigated the comparative effectiveness of resilience-focused psychological interventions — including CBT, positive psychology interventions, and ACT — on three outcomes critical to cancer patient well-being: resilience, anxiety, and depression. Because existing evidence had been largely limited to head-to-head pairwise comparisons, a more comprehensive ranking of these approaches had not previously been established for oncology populations.
How It Was Studied
Researchers conducted a systematic search across seven major databases (CINAHL, Embase, MEDLINE Ovid, PubMed, Scopus, Web of Science, and Cochrane) from inception through December 2025. Twenty-six randomized controlled trials totaling 2,159 adults with cancer were identified and pooled. A frequentist random-effects network meta-analysis was performed using the netmeta package in R, allowing simultaneous comparison of multiple intervention types against usual care and against each other. Effectiveness was quantified using standardized mean differences (SMDs) with 95% confidence intervals, prediction intervals, P-scores, and certainty of evidence ratings.
What Was Observed
- CBT produced the largest resilience improvement of any intervention evaluated, representing a large effect approximately one full standard deviation above control (SMD = 1.14, 95% CI: 0.80–1.48). Positive psychology interventions ranked second for resilience (SMD = 0.79, 95% CI: 0.56–1.03), a moderate-to-large effect with a notably tighter confidence interval, suggesting a more precise estimate.
- ACT showed the numerically largest average anxiety reduction, though the confidence interval was wide, indicating meaningful uncertainty in the estimate (SMD = −0.97, 95% CI: −1.85 to −0.10). CBT also reduced anxiety significantly and with greater precision (SMD = −0.73, 95% CI: −1.19 to −0.27), reflecting a moderate-to-large reduction in symptom burden.
- For depression, CBT and positive psychology both achieved statistically significant reductions. CBT’s depression effect was moderate (SMD = −0.61, 95% CI: −0.97 to −0.25), and positive psychology interventions produced a comparable reduction (SMD = −0.55, 95% CI: −0.89 to −0.20), with similarly narrow confidence intervals suggesting reliable estimates for both.
- ACT’s resilience estimate carried substantial uncertainty, with a wide confidence interval crossing only marginally above zero (SMD = 0.70, 95% CI: 0.04–1.35), meaning its benefit for resilience, while positive in direction, should be interpreted cautiously.
Why This Matters
Cancer patients commonly experience psychological distress that reduces resilience and elevates anxiety and depression, yet the comparative standing of different resilience-focused interventions had remained unclear due to the limitations of pairwise trial designs. This network meta-analysis is the first to rank these approaches simultaneously across multiple outcomes in oncology, providing clinicians with actionable evidence on which interventions offer the broadest and most consistent psychological benefits. The findings directly support calls to integrate structured resilience-based psychological therapies — particularly CBT — into standard oncology care pathways.
How to Read This Result
These findings are directionally positive and methodologically strengthened by the network design, but the moderate overall study quality signal, likely heterogeneity across cancer types and intervention delivery formats, and the wide confidence intervals observed for ACT in particular warrant caution when generalizing to specific patient populations or clinical settings.
Limitations
The abstract does not explicitly report study limitations.